Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases
Journal of Medicinal Chemistry2013Vol. 56(5), pp. 2059–2073
Citations Over TimeTop 10% of 2013 papers
Matt Addie, Peter Ballard, David Buttar, Claire Crafter, Gordon S. Currie, Barry R. Davies, J.E. Debreczeni, Hannah Dry, Philippa Dudley, Ryan Greenwood, Paul D. Johnson, Jason G. Kettle, Clare Lane, Gillian M. Lamont, Andrew G. Leach, Richard Luke, Jeff Morris, Donald Ogilvie, Ken Page, Martin Pass, Stuart E. Pearson, Linette Ruston
Abstract
Wide-ranging exploration of analogues of an ATP-competitive pyrrolopyrimidine inhibitor of Akt led to the discovery of clinical candidate AZD5363, which showed increased potency, reduced hERG affinity, and higher selectivity against the closely related AGC kinase ROCK. This compound demonstrated good preclinical drug metabolism and pharmacokinetics (DMPK) properties and, after oral dosing, showed pharmacodynamic knockdown of phosphorylation of Akt and downstream biomarkers in vivo, and inhibition of tumor growth in a breast cancer xenograft model.
Related Papers
- → Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel(2005)39 cited
- → Identification and characterization of a novel genetic mutation with prolonged QT syndrome in an unexplained postoperative death(2013)10 cited
- → Pharmacological rescue of hERG currents carried out by G604S and wide type hERG co‐expression(2016)2 cited
- → Robust Deep Learning Architecture for hERG-related Cardiotoxicity Prediction on Small-Scale Dataset(2022)